One of those trials (FOCULM trial) about mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer showed the median OS of 33.2 months in the control group (mFOLFOXIRI only). The gene discussed is BRAF; the disease is colorectal cancer.